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ABSTRACT
Background: Binge-eating disorder may represent a risk factor for
the metabolic syndrome.
Objective: The objective was to assess longitudinally the relation
between binge-eating disorder and components of the metabolic
syndrome.
Design: At 2.5 and 5 y of follow-up, 134 individuals with binge-
eating disorder and 134 individuals with no history of eating dis-
orders, who were frequency-matched for age, sex, and baseline
body mass index (BMI), were interviewed during the follow-up
interval regarding new diagnoses of 3 metabolic syndrome compo-
nents: hypertension, dyslipidemia, and type 2 diabetes.
Results: A comparison of individuals with and without a binge-
eating disorder in analyses adjusted for age, sex, baseline BMI,
and interval BMI change had hazard ratios (95% CIs) for reporting
new diagnoses of metabolic syndrome components of 2.2 (1.2, 4.2;
P = 0.023) for dyslipidemia, 1.5 (0.76, 2.9; P = 0.33) for hyperten-
sion, 1.6 (0.77, 3.9; P = 0.29) for type 2 diabetes, 1.7 (1.1, 2.6; P =
0.023) for any component, and 2.4 (1.1, 5.7; P = 0.038) for 2
components.
Conclusion: Binge-eating disorder may confer a risk of compo-
nents of the metabolic syndrome over and above the risk attributable
to obesity alone. This trial was registered at www.clinicaltrials.gov
as NCT00777634. Am J Clin Nutr 2010;91:1568–73.
INTRODUCTION
The metabolic syndrome is a cluster of related risk factors for
atherosclerotic cardiovascular disease, including abdominal
obesity, dyslipidemia, hypertension, and abnormal glucose me-
tabolism (1–3); it represents a growing public health problem
(4), Binge-eating disorder is a recently proposed psychiatric
condition characterized by recurrent episodes of binge eating—
consuming abnormally large amounts of food in a discrete period
of time (eg,,2 h), associated with a sense of loss of control over
eating. Binge-eating disorder is associated with subjective dis-
tress but lacks the purging (eg, self-induced vomiting or laxative
abuse) seen in bulimia nervosa (5, 6). It is common (with
a lifetime prevalence of 1–3% in the United States and Western
Europe; 7–9), increasing in prevalence (7), and frequently as-
sociated with other psychiatric and medical conditions, in-
cluding obesity (7, 10, 11). Binge-eating disorder may be
associated with the metabolic syndrome, as tentatively sug-
gested by studies assessing metabolic syndrome components in
individuals with binge-eating disorder (10, 12–14) and con-
versely by some (15–17), although not all (18), studies assessing
the prevalence of binge eating among individuals with type 2
diabetes. However, past studies have been largely cross-sectional
and possibly vulnerable to selection and reporting bias, limiting
inferences regarding the nature of the relation between binge-
eating disorder and the metabolic syndrome (6, 19). To further
illuminate this issue, we report here a 5-y longitudinal evalua-
tion of individuals with binge-eating disorder.
SUBJECTS AND METHODS
In a previous family study that we conducted (11), between
October 2002 and July 2004, we interviewed 300 overweight or
obese probands aged 18 y, recruited by advertisement from the
community, of whom 150 displayed current or past binge-eating
disorder by Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition (DSM-IV) (5) criteria (Appendix A), and
150 displayed no history of an eating disorder by DSM-IV
criteria. We also interviewed 888 of these participants’ first-
degree relatives. All interviews were performed by psychiatrist
investigators (HGP, JKL, or JIH).
1 From the Biological Psychiatry Laboratory, McLean Hospital, Belmont,
MA, and the Department of Psychiatry, Harvard Medical School, Boston,
MA (JIH, JKL, CEC, and HGP); the Institute of Behavioral Genomics, De-
partment of Psychiatry, University of California at San Diego, San Diego,
CA, and the Harvard Institute of Psychiatric Epidemiology & Genetics,
Boston, MA (MTT); the Lindner Center of HOPE, Mason, OH, and the
Department of Psychiatry, University of Cincinnati College of Medicine,
Cincinnati, OH (SLM); the Department of Psychiatry, University of Minne-
sota, Minneapolis, MN (SJC); the Departments of Psychiatry and Nutrition,
University of North Carolina at Chapel Hill, Chapel Hill, NC (CMB); the
Division of Endocrinology, Brigham and Women’s Hospital, Boston, MA,
and the Department of Medicine, Harvard Medical School, Boston, MA
(MSH); the Unit on Growth and Obesity, Program in Developmental Endo-
crinology and Genetics, Eunice Kennedy Shriver National Institute of Child
Health and Human Development, National Institutes of Health, Bethesda,
MD (JAY); and Ortho-McNeil Pharmaceutical Inc, Raritan, NJ (NRR).
2 Supported in part by an investigator-initiated grant from Ortho-McNeil
Janssen Scientific Affairs (principal investigator: JIH) and by Z01-HD-00641
(principal investigator: JAY) from the Intramural Research Program of the
NICHD, NIH.
3 Address correspondence to JI Hudson, McLean Hospital, 115 Mill
Street, Belmont, MA 02478. E-mail: jhudson@mclean.harvard.edu.
Received January 13, 2010. Accepted for publication March 30, 2010.
First published online April 28, 2010; doi: 10.3945/ajcn.2010.29203.
1568 Am J Clin Nutr 2010;91:1568–73. Printed in USA.  2010 American Society for Nutrition
Approximately 2.5 and 5 y later, we followed up probands and
relatives who had reported current binge-eating disorder at
baseline, together with comparison probands and relatives with
no history of an eating disorder, who were frequency-matched for
age, sex, and baseline BMI to the individuals with binge-eating
disorder. All participants provided written informed consent
before initiating the study, which was approved by the McLean
Hospital Institutional Review Board.
At follow-up, the psychiatrist investigators (JIH, JKL, or HGP)
assessed by interview whether participants reported the new di-
agnosis of any of 3 components of the metabolic syndrome—
dyslipidemia (as indicated by hypercholesterolemia), hypertension,
or type 2 diabetes—during the follow-up interval, operationally
defined as 1) receiving a new diagnosis of the disorder from
a health care provider or 2) receiving pharmacologic treatment of
the disorder for the first time (eg, receiving a statin-type agent after
having never previously received any lipid-lowering drug). For
thosewith a report of a new diagnosis, the time of diagnosis within
the follow-up interval was obtained to the nearest month based on
the participant’s self-report. These investigators also administered
a structured interview to assess health care utilization during the
follow-up interval, which included the number of visits to health
care professionals. Interviews were conducted in person, except
for a small number of interviews thatwere performedby telephone
for individuals who could not come in for evaluation (at baseline,
n = 1; at 2.5 y, n = 15; at 5 y, n = 12). BMI was calculated based on
measured height (m2) and weight (kg), except for the individuals
interviewed by telephone, who provided self-report of height and
weight. Participants also completed the self-report Bad Things
Scale (20), whichwas used in sensitivity analyses to control for the
tendency to overreport adverse experiences (see Results).
Although the outcomes assessed were components of the
metabolic syndrome, it should be noted that we were not able to
assess the full Adult Treatment Panel III (ATP III) (1) definition
of metabolic syndrome, because the full assessment of this
construct would have required baseline and follow-up meas-
urements of waist circumference, serum lipids, blood pressure,
and glucose, which we did not obtain.
As our main analysis, we calculated hazard ratios for diagnosis
of the metabolic syndrome components in individuals with
baseline binge-eating disorder compared with comparison indi-
viduals, using a proportional hazards model adjusting for age,
sex, race-ethnicity, baseline BMI (using categories representing
quintiles of the distribution of BMI), change in BMI over the
follow-up interval, proband compared with relative status, and
diagnosis of each of the other components before developing the
component under evaluation. Note that the adjustment for change
in BMI over follow-up is only a proxy for the ideal adjustment,
which would be the serial measurement of BMI, entered as
a time-varying covariate. However, because there was little
difference between groups in weight gain over follow-up (see
Results), it is very unlikely that differential weight gain between
groups influenced the findings in any event. SEs were adjusted
for the correlation of observations within families (because
some individuals were relatives of one another).
No violations of the proportional hazards assumption were
detected by inspection of log-log plots or by a test of weighted
residuals (21). Pooling of data across probands and relatives appeared
justified in that there were no significant interactions between type of
participant (proband compared with relative) and group.
Alpha was 0.05, 2-tailed, except for testing interactions, for
which it was 0.1, 2-tailed. All analyses were performed by using
Stata version 9.2 (Stata Corp, College Station, TX).
RESULTS
Of159eligible individuals found tohavebinge-eatingdisorder
at baseline (100 probands and 59 relatives), 137were evaluated at
2.5 y and 129 at 5 y (ie, 94% of the individuals seen at 2.5 y were
again seen at 5 y). We evaluated 138 comparison probands and
relatives at 2.5 y (selected from the pool of individuals without
eating disorders, as described above) and 133 at 5 y (96% of the
individuals seen at the 2.5 y). Seven individuals (3 with binge-
eating disorder and 4 without) already had a diagnosis of all 3
metabolic syndrome components at baseline, which left 134
individuals in each group at risk of at least one component, which
formed the sample for this study (Table 1). The groups did not
differ significantly in age, sex, or weight change during follow-
up. However, the group with baseline binge-eating disorder had
a significantly greater baseline BMI than did the comparison
TABLE 1
Baseline characteristics of and 5-y follow-up observations in individuals with and without a binge-eating disorder at baseline1
Characteristic Binge-eating disorder (n = 134) No binge-eating disorder (n = 134) P2
Baseline age (y) 47.0 6 13.23 47.8 6 12.9 0.56
Female sex [n (%)] 107 (80) 102 (76) 0.56
Race-ethnicity [n (%)]
White, non-Hispanic 119 (89) 129 (96) 0.034
African American 14 (10) 5 (4)
Hispanic 1 (1) 0
Baseline BMI (kg/m2) 36.1 6 7.5 34.5 6 5.7 0.046
Follow-up time (mo), median (interquartile range)4 61.0 (60.1, 62.2) 60.8 (59.8, 62.4) 0.48
Change in BMI over follow-up interval (kg/m2) 0.0 6 4.9 0.5 6 3.6 0.33
1 Of the 137 individuals with binge-eating disorder seen for at least one follow-up visit, 3 were excluded from analysis because they already had
a diagnosis of all 3 metabolic syndrome components at baseline; for the individuals without binge-eating disorder, the number is reduced from 138 to 134 for
the same reason.
2 P values from t test for continuous variables (except follow-up time), Fisher’s exact test for categorical variables, and Wilcoxon’s rank-sum test for
follow-up time; all tests were 2-tailed.
3 Mean 6 SD (all such values).
4 All participants were evaluated at the 2.5-y follow-up, and 96% were evaluated at both 2.5 and 5 y.
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group (Table 1). The difference in baseline BMI reflected a slight
failure of our frequency matching, largely because our pool of
comparison probands was not large enough to allow perfect
matching on BMI after having matched for age and sex. In ad-
dition, the binge-eating disorder group consisted of significantly
fewer individuals who were in the white non-Hispanic category
of race-ethnicity (Table 1). Note that all analyses controlled for
baseline BMI and race-ethnicity (as well as age and sex) to
prevent differences between groups in these variables from in-
troducing bias due to confounding.
Individuals with baseline binge-eating disorder reported
a higher 5-y incidence of diagnoses of hypertension, dyslipi-
demia, type 2 diabetes, any metabolic syndrome component, and
2 metabolic syndrome components than comparison in-
dividuals (Table 2; Figure 1), with hazard ratios ranging from
1.5 to 2.4 (Table 3). The hazard ratios for a diagnosis of dys-
lipidemia, for any metabolic syndrome component, and for 2
metabolic syndrome components were statistically significant.
Note that only 2 individuals developed 3 metabolic syndrome
components (one in each group), so that a statistical test of the
difference between groups on this outcome was not possible.
We performed additional analyses to test for possible bias due to
1) differential opportunities for detection of disorders—by ad-
justing for the frequency of visits to health care providers during
the follow-up interval; 2) differential reporting of adverse events
(such as medical diagnoses)—by adjusting for “adversity over-
reporting,” based on data obtained from the Bad Things Scale
using methods described elsewhere (22); and 3) selection bias in
sampling of probands—by restricting the analysis to relatives
only. The first 2 analyses produced estimates similar to those of
the main analysis, whereas the third further increased many of the
estimates (Table 3). We also tested for overreporting by nar-
rowing the case definition to individuals who not merely had
a diagnosis but who began pharmacotherapy for a new disorder
during the follow-up interval; this analysis again had little effect
on most of the estimates (Table 3).
Finally, we examined the extent to which the associations
might be influenced by baseline BMI (in particular, whether
higher baseline BMI would be associated with higher hazard
ratio), and found no significant interactions between binge-eating
disorder and baseline BMI.
DISCUSSION
In a 5-y longitudinal study, community individuals with binge-
eating disorder had statistically significant increases of 2.2-fold in
the hazard for a new diagnosis of dyslipidemia, 1.7-fold in the
hazard for a new diagnosis of any component of the metabolic
syndrome (hypertension, dyslipidemia, or type 2 diabetes), and
2.4-fold in the hazard for a new diagnosis of 2 or more metabolic
syndrome components relative to a BMI-matched comparison
group without binge-eating disorder. Dyslipidemia was the only
individual metabolic syndrome component with a hazard ratio
reaching statistical significance in the comparisons, hazard ratios
for all components were elevated, and hazard ratios for any and
for 2 components were statistically significantly elevated.
These findings represent, to our knowledge, the first longi-
tudinal evidence that binge-eating disorder may increase the risk
of components of the metabolic syndrome independent of the risk
conferred by obesity alone, because the hazard ratios were
significantly elevated even after baseline BMI and change in BMI
were controlled for over the follow-up interval. The nature of this
obesity-independent effect remains unknown. It might represent
a direct effect of binge eating, perhaps due to the large amount of
food—often in the range of 2000 to 5000 kcal—ingested in
typical eating binges (23). For example, rapid consumption of
TABLE 2
New diagnoses of metabolic syndrome components over 5 y of follow-up in individuals with and without a binge-eating disorder at baseline










n n (%) n n (%)
Dyslipidemia 115 34 (30) 109 18 (17)
Hypertension 104 25 (24) 102 18 (18)
Type 2 diabetes 124 13 (10) 128 10 (8)
Any metabolic syndrome component 134 53 (40) 134 37 (28)
Two or more metabolic syndrome components 124 18 (15) 120 8 (7)
Three metabolic syndrome components 85 1 (1) 85 1 (1)
1 Number at risk of developing a given component of the metabolic syndrome: for any component, represents the number lacking at least one component
at baseline; for 2 components, represents the number lacking 2 components at baseline; and for 3 metabolic syndrome components, represents the number
without any component at baseline.
2 Number reporting new diagnosis of component or set of components during the follow-up interval.
FIGURE 1. Kaplan-Meier estimates of new diagnoses of any metabolic
syndrome component, by group.
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large amounts of food can increase oxidative and inflammatory
stress (24, 25), and inflammatory changes are hypothesized to
represent an important causal pathway for developing metabolic
syndrome components (26–29). Alternatively, because binge-
eating disorder appears to be partially caused by genetic factors
independent of obesity (11, 30), it is possible that these or other
underlying nongenetic factors might increase the risk of the
metabolic syndrome via separate causal pathways not mediated
by binge-eating disorder or obesity. For example, we have shown
that binge-eating disorder shares common familial factors with
mood disorders (major depressive disorder and bipolar disorder)
(31, 32). Mood disorders, in turn, are associated with the met-
abolic syndrome (33–35). Also, other unmeasured factors (eg,
smoking) might represent, like obesity, intermediate variables on
the causal pathway from binge-eating disorder to metabolic
syndrome components and thus result in associations between
binge-eating disorder and metabolic syndrome components that
are not direct effects of binge-eating behavior.
A strength of our study was that it used community partic-
ipants, rather than a clinical sample, thus minimizing the pos-
sibility of selection bias. Nevertheless, several limitations should
be considered. First, data were based on self-report rather than on
serial physiologic measurements of metabolic syndrome com-
ponents, inspection of medical records, or pill counts. However,
error from self-report would likely be nondifferential across
groups. Second, interviewers were nonblinded. However, reports
of medical diagnoses or drug initiation are generally un-
ambiguous and thus are rarely susceptible to observer bias. Third,
differences between groups might represent an artifact caused by
differential detection or reporting—but analyses that controlled
for both of these possibilities produced little change in the
findings. Fourth, differences between groups might be attribut-
able to differential diagnostic evaluation or treatment based on
health care providers’ knowledge of the diagnosis of binge-eating
disorder. In other words, health care providers might be more
likely to pursue diagnostic testing for metabolic syndrome
components (such as measurement of fasting glucose and lipid
concentrations) in someone with known binge-eating disorder
and, thus, might be more likely to detect metabolic syndrome
components in these individuals. Similarly, health care providers
might be more likely to prescribe pharmacotherapy rather than
a dietary intervention to someone with known binge-eating
disorder who displayed one of these metabolic syndrome com-
ponents. However, it is our impression from the study that most
health care providers were not aware of the diagnoses of binge-
eating disorder in these individuals, which argues against this
possibility. Fifth, individuals with binge-eating disorder might be
more likely to receive pharmacotherapy for psychiatric disorders,
and pharmacotherapy in turn might potentiate weight gain.
However, the 2 groups did not differ in change in BMI, so that any
differential effect due to psychiatric medications would have to
have been independent of weight gain. Sixth, despite being drawn
from the community, the probands in our study might not have
been representative of their source population. However, their
relatives would be much less vulnerable to selection bias, and the
analysis restricted to relatives produced hazard ratios higher than
those observed in the pooled sample. Seventh, the individuals
with binge-eating disorder had a high mean BMI at baseline
(36.1); thus, the results may not generalize to individuals with
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(23%) of our cases of binge-eating disorder were not obese (BMI
, 30) and that we found no significant interaction between
binge-eating disorder and baseline BMI in the association with
new diagnoses of metabolic syndrome components, it is unlikely
that the association is unique to obese individuals with binge-
eating disorder. Eighth, it is possible that the 2 study groups
differed in terms of unmeasured factors that influence both
metabolic syndrome and binge-eating disorder; thus, the failure to
adjust for these factors might have introduced bias through con-
founding.
In summary, our findings suggest the possibility that binge-
eating disorder confers risk of components of the metabolic
syndrome over and above the risk conferred by obesity alone.
Given the mounting public health threat posed by the metabolic
syndrome, it will be important to test this hypothesis definitively
in a manner that would also seek possible mechanisms for this
apparent obesity-independent risk. Findings in this area may have
substantial public health significance, because binge-eating
disorder is common (7–9) and frequently treatable (36–41).
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APPENDIX A
Diagnostic and Statistical Manual of Mental Disorders, 4th
edition, criteria for binge-eating disorder (5)
A. Recurrent episodes of binge eating. An episode of binge
eating is characterized by both of the following:
1) Eating, in a discrete period of time (eg, within any 2-h
period), an amount of food that is definitely larger than
most people would eat in a similar period of time under
similar circumstances
2) A sense of lack of control over eating during the episode
(ie, feeling that one cannot stop eating or control what or
how much one is eating).
B. The binge-eating episodes are associated with 3 (or more) of
the following:
1) Eating much more rapidly than normal
2) Eating until feeling uncomfortably full
3) Eating large amounts of food when not feeling physically
hungry
4) Eating alone because of being embarrassed by how much
one is eating
5) Feeling disgusted with oneself, depressed, or very guilty
after overeating
C. Marked distress regarding binge eating is present.
D. The binge eating occurs, on average, 2 d/wk for 6 mo.
E. The binge eating is not associated with the regular use of
inappropriate compensatory behaviors (eg, purging, fasting,
excessive exercise) and does not occur exclusively during the
course of Anorexia Nervosa or Bulimia Nervosa.
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